These posters, oral presentations, and/or abstracts are provided for medical and scientific purposes only, they may include investigational use or agents that are not approved by health authorities. The information presented is not meant to convey conclusions of safety or effectiveness prior to any regulatory approval from a health authority.
Sanofi does not recommend the use of any products in a manner inconsistent with that described in the full prescribing information. Please refer to the prescribing information in your country of practice for any medicinal products mentioned.
Availability of posters and/or abstracts on this site will conform with conference embargo policies. By selecting “Accept”, you are certifying that you are a Healthcare Professional.
EHA 2024 | Jun 13, 2024 - Jun 16, 2024
Cold Agglutinin Disease (CAD) is a rare type of chronic, autoimmune, hemolytic anemia. In people with CAD, the body’s immune system mistakenly attacks and destroys healthy red blood cells (hemolysis) by activating the “classical complement” pathway, part of the innate immune system. People with CAD may experience chronic anemia, profound fatigue, acute hemolytic crisis, and other potentially serious complications.
